The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
Open accessAbstract
Objectives: Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates. Methods: We retrospectively analysed 32 patients with confirmed MERS-CoV infection, admitted between April 2014 and June 2014, by positive respiratory sample RT–PCR. Plasma MERS-CoV RT–PCR was performed at the time of diagnosis for 19 patients. Results: The overall mortality rate was 69% (22/32). Ninety percent (9/10) of patients with positive plasma MERS-CoV PCR died compared with 44% (4/9) of those with negative plasma MERS-CoV PCR. Mortality rate in patients who received IFN-α2a was 85% (11/13) compared with 64% (7/11) in those who received IFN-β1a (P = 0.24). The mortality rate in patients with renal failure (14), including 8 on haemodialysis, was 100%. Age >50 years and diabetes mellitus were found to be significantly associated with mortality (OR = 26.1; 95% CI 3.58–190.76; P = 0.001 and OR = 15.74; 95% CI 2.46–100.67; P = 0.004, respectively). The median duration of viral shedding in patients who recovered was 11 days (range 6–38 days). Absence of fever was noted in 5/32 patients. Conclusions: Plasma MERS-CoV RT–PCR may serve as an effective tool to predict MERS-CoV-associated mortality. Older age and comorbid conditions may have contributed to the lack of efficacy of IFN-α2a or IFN-β1a with ribavirin in treating MERS-CoV. Absence of fever should not exclude MERS-CoV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Cited by
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30172-5 · Cited by 1,350
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Badawi, A., & Ryoo, S. G. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.06.015 · Cited by 703
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Middle East Respiratory Syndrome
Arabi, Y. M., Balkhy, H. H., Hayden, F. G., Bouchama, A., Luke, T., Baillie, J. K., Al-Omari, A., Hajeer, A. H., Senga, M., Denison, M. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1408795 · Cited by 518
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
Recent discovery and development of inhibitors targeting coronaviruses
Pillaiyar, T., Meenakshisundaram, S., & Manickam, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.015 · Cited by 361
Effective inhibition of MERS-CoV infection by resveratrol
Lin, S.-C., Ho, C.-T., Chuo, W.-H., Li, S., Wang, T. T., & Lin, C.-C. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2253-8 · Cited by 358
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses.
Shen, L., Niu, J., Wang, C., Huang, B., Wang, W., Zhu, N., Deng, Y., Wang, H., Ye, F., Cen, S., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00023-19 · Cited by 319
Cao, B., Huang, Y., She, D., Cheng, Q., Fan, H., Tian, X., Xu, J., Zhang, J., Chen, Y., Shen, N., et al. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12674 · Cited by 300
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00773-9 · Cited by 295
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Self-citationNucleoside analogues for the treatment of coronavirus infections
Pruijssers, A. J., & Denison, M. R. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.002 · Cited by 196
Metadata
- Authors
- Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., & Mushtaq, A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-21
- Volume
- 70
- Issue
- 7
- Pages
- 2129-2132
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2153006252
- Cited by
- 189
- References
- 1
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.